

Correction: Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?

Toby A. Eyre

Early Phase Trials Unit, University of Oxford, Oxford, UK; Department of Clinical Haematology, Oxford Cancer Centre, Churchill Hospital, Oxford, UK

Published: February 26, 2019

Copyright: Eyre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The correct 10 th reference is given below:

10. Eyre TA, et al. Cancer. 2019; 125:99-108. <https://doi.org/10.1002/cncr.31791>.

Oncotarget. 2018; 9:37280-37281. <https://doi.org/10.18632/oncotarget.26460>